The antileishmanial efficacy of the reference drug N-methylglucamine antimoniate (Glucantime) was evaluated in groups of rhesus monkeys with acute and chronic Leishmania (Viannia) braziliensis cutaneous infection. The therapeutic responses in experimental animals to either a low dose (5 mg/kg body wt/day for 28 days) or a routine dose (20 mg/kg/day for 28 days) of pentavalent antimony were similar to those reported in the human disease. Primates were cured of their lesions after treatment, but with cryptic parasitism and/or relapse. The rhesus model of L. (V.) braziliensis cutaneous leishmaniasis therefore provides an additional resource for preclinical trials with newer drugs.

Download full-text PDF

Source
http://dx.doi.org/10.1645/GE-3486RN.1DOI Listing

Publication Analysis

Top Keywords

braziliensis cutaneous
12
leishmania viannia
8
viannia braziliensis
8
cutaneous infection
8
n-methylglucamine antimoniate
8
responses leishmania
4
infection n-methylglucamine
4
antimoniate rhesus
4
rhesus monkey
4
monkey macaca
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!